Malta - angličtina - Medicines Authority

hospira uk limited horizon, honey lane, hurley, maidenhead sl6 6rj, united kingdom - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2.330 g - antibacterials for systemic use

Spojené státy - angličtina - NLM (National Library of Medicine)

sandoz gmbh - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

Spojené státy - angličtina - NLM (National Library of Medicine)

sandoz gmbh - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae, staphylococcus aureus, hae

Spojené státy - angličtina - NLM (National Library of Medicine)

remedyrepack inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: caused by streptococcus pneumoniae , staphylococcus aureus, ha

Malta - angličtina - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection - ceftazidime pentahydrate 500 milligram(s) - antibacterials for systemic use

Malta - angličtina - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - solution for injection/infusion - ceftazidime pentahydrate 1 gram(s) - antibacterials for systemic use

Malta - angličtina - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftazidime pentahydrate - powder for solution for injection/infusion - ceftazidime pentahydrate 2 gram(s) - antibacterials for systemic use

Malta - angličtina - Medicines Authority

pharmsol europe limited the victoria centre unit 2, lower ground floor, valletta road, mosta mst 9012 , malta - ceftriaxone sodium - powder for solution for infusion - ceftriaxone sodium 2 gram(s) - antibacterials for systemic use

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

jed pharma limited - ceftriaxone sodium - solution for injection/infusion - ceftriaxone

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ceftazidime pentahydrate 1164.8mg equivalent to 1 g ceftazidime - powder for injection - 1 g - active: ceftazidime pentahydrate 1164.8mg equivalent to 1 g ceftazidime excipient: nitrogen sodium carbonate - ceftazidime sandoz is indicated for the treatment of single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. indications include: severe infections e.g. septicaemia, bacteraemia, peritonitis, meningitis; infections in immunosuppressed patients; infections in patients in intensive care, e.g. infected burns; respiratory tract infections including lung infections in cystic fibrosis; ear, nose and throat infections; urinary tract infections; skin and soft tissue infections; gastrointestinal, biliary and abdominal infections; bone and joint infections; infections associated with haemo-and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).